(NEO) NeoGenomics, Inc. Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(NEO) NeoGenomics, Inc. Complete Analysis Pack
Download Your Competitive Advantage
This NeoGenomics, Inc. 4P's Marketing Mix Analysis shows how the company’s Product, Price, Place, and Promotion choices support its market positioning and growth; it’s designed for marketing research, strategy, and competitive benchmarking. The page includes a real preview/sample of the analysis so you can check format and depth—purchase the full version to get the complete ready-to-use report.
Product
2 divisions: Clinical Services and Pharma Services
NeoGenomics, Inc. runs two divisions: Clinical Services and Pharma Services. Clinical Services supports diagnosis and treatment decisions for patients and providers, while Pharma Services helps oncology drug development from discovery to commercialization. The model spans the full cancer testing workflow and, in 2024, NeoGenomics reported about $636 million in revenue.
Cancer-focused laboratory testing
NeoGenomics, Inc.’s core product is a broad oncology test menu that helps detect, classify, and monitor cancer across many tumor types. The company serves hospitals, reference labs, pathologists, oncologists, and clinicians with lab diagnostics built for treatment decisions. In 2024, NeoGenomics reported $650M+ in revenue, showing demand for its cancer testing platform.
Cytogenetics, FISH, and flow cytometry
NeoGenomics, Inc. uses cytogenetics, FISH, and flow cytometry to spot chromosome changes, gene targets, and cell-population shifts linked to cancer and related disorders. These tests support faster, clearer diagnosis and help doctors classify disease risk. They sit inside NeoGenomics’ advanced diagnostic platform and strengthen its precision oncology offering.
Immunohistochemistry and digital imaging
NeoGenomics, Inc. uses immunohistochemistry to localize proteins in tissue and digital imaging to review scanned pathology slides, helping pathologists see patterns faster and more clearly. The digital workflow supports quantitative analysis, which can improve diagnostic accuracy and reduce manual review time. In 2025, this kind of slide digitization became a core lab efficiency tool across high-volume oncology testing.
- Tissue-based protein localization
- Scanned-slide review and analysis
- Higher diagnostic consistency
- Faster pathology workflows
Molecular testing and morphologic analysis
NeoGenomics’ molecular testing and morphologic analysis combines DNA and RNA profiling with microscopic pathology review, so oncologists can see both the tumor’s genetic drivers and its cell-level structure. This mixed method helps detect mutations, fusions, and visible abnormalities in one workup, which can sharpen diagnosis and treatment selection. It also gives pathologists and clinicians broader context when assessing complex cancers.
- DNA and RNA plus pathology review
- Finds genetic and cellular changes
- Supports more precise oncology decisions
NeoGenomics: Broad Oncology Testing Powering Cancer Care
NeoGenomics, Inc.’s product is a broad oncology testing portfolio that combines molecular testing, cytogenetics, FISH, flow cytometry, immunohistochemistry, and digital pathology. It supports diagnosis, risk stratification, and treatment selection for hospitals, oncologists, and labs. The mix spans both Clinical Services and Pharma Services, and NeoGenomics reported about $636 million in 2024 revenue.
| Product element | Use | Value |
|---|---|---|
| Oncology test menu | Cancer diagnosis and monitoring | Broad clinical coverage |
| Digital pathology | Slide review and quant analysis | Faster workflows |
| Molecular testing | DNA and RNA profiling | Better treatment decisions |
| 2024 revenue | Company scale | About $636 million |
What is included in the product
Detailed Word Document
A concise, company-specific 4P analysis of NeoGenomics, Inc.’s Product, Price, Place, and Promotion strategy for clear strategic insight.
Editable Excel File
Condenses NeoGenomics’ 4Ps into a quick, clear view that eases analysis, alignment, and presentation prep.
Reference Sources
Provides a concise, traceable bibliography linking NeoGenomics’ key claims to industry reports, datasets, and benchmarks to speed due diligence and verify assumptions.
Place
Headquartered in Fort Myers, Florida
NeoGenomics, Inc. is headquartered in Fort Myers, Florida, where it anchors corporate operations, commercial management, and network coordination. That base supports its U.S.-centered testing platform while helping manage international reach across a broader oncology diagnostics network.
Laboratories across the United States
NeoGenomics, Inc. runs a broad U.S. lab network, including major facilities in Aliso Viejo, California, and Fort Myers, Florida, with additional regional sites that place testing closer to clients. That footprint helps reduce transit time, speed turnaround, and widen access for oncology and clinical customers. In 2025, the company reported about $567 million in net revenue, showing the scale behind this service model.
Operations in Europe and Asia
NeoGenomics extends its reach into Europe and Asia through its global pharma and clinical testing network, supporting cross-border oncology diagnostics and drug development. This matters for multinational research programs, since global oncology spending is still rising and pharma trials now routinely span several regions. A broader footprint also helps NeoGenomics serve clients that need matched testing, faster sample routing, and more consistent data across markets.
Direct service to hospitals and reference laboratories
NeoGenomics, Inc. sells cancer testing directly to hospitals and reference laboratories, not through retail channels, which matches its B2B model. These two channels drive most test volume and support high-complexity oncology work, where clinical labs need a specialist partner.
That setup fits the market: NeoGenomics reported more than 1 million tests processed annually, and large health systems can route orders into its network for faster access to molecular and pathology services.
- Direct B2B distribution
- Hospitals and reference labs drive volume
- Best suited to specialist cancer diagnostics
Strategic alliance with Inivata Limited
NeoGenomics, Inc. uses the Strategic alliance with Inivata Limited to coordinate laboratory services and widen reach beyond its core sites. Partnerships like this help NeoGenomics extend geographic coverage and add technical depth without building every capability in-house.
- Expands service reach
- Supports lab coordination
- Adds technical capability
- Helps cover more geographies
NeoGenomics’ U.S. Lab Network Speeds Oncology Testing
NeoGenomics, Inc. places its core hub in Fort Myers, Florida, and runs major lab sites in Aliso Viejo, California, plus other U.S. facilities to keep oncology samples close to customers and speed turnaround.
Its place strategy is mainly B2B, serving hospitals and reference labs through direct lab-to-lab delivery, with Europe and Asia links for pharma and clinical testing.
| Place factor | Data |
|---|---|
| HQ | Fort Myers, Florida |
| Major U.S. labs | Aliso Viejo and Fort Myers |
| 2025 net revenue | $567 million |
| Primary channel | Direct B2B to hospitals |
Preview Before You Purchase
NeoGenomics, Inc. Reference Sources
The preview shown here is the actual NeoGenomics, Inc. 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.
Promotion
B2B sales to oncology stakeholders
NeoGenomics sells directly to hospitals, oncologists, clinicians, and labs, so its promotion depends on relationship-based outreach, not mass marketing. That fit matters in oncology, where referral cycles are long and clinical trust drives adoption. In recent years, NeoGenomics has used this channel mix to support over $600 million in annual revenue, tying sales activity to test uptake and referral growth.
Pharma client development support
NeoGenomics promotes Pharma Services to biopharma teams in oncology, backing programs from discovery through commercialization. That fits a drug path that often runs 10 to 15 years and can cost over $1 billion, so the message is clear: NeoGenomics is a development partner, not just a test vendor. The offer targets higher-value pharma work as oncology R&D stays one of the largest spending areas in 2025.
Medical and scientific credibility
NeoGenomics promotes medical credibility by stressing clinical evidence, advanced testing, and specialist review. Its CLIA- and CAP-accredited labs and focus on oncology diagnostics help build trust with ordering physicians and research partners, so proof of quality matters as much as price. In diagnostics, strong lab science is the message.
Reference laboratory positioning
NeoGenomics, Inc. positions itself as a reference lab for anatomic pathology testing, which helps frame it as a specialist for complex, high-acuity cases. That message supports trust and expertise, especially in molecular and pathology work where accuracy matters most. In 2025, the company still operated at scale, with annual revenue in the hundreds of millions, backing that specialist image.
- Specialist case handling
- Higher trust signal
- Supports complex testing
Partnership-based visibility
NeoGenomics, Inc. uses partnership-based visibility to widen market reach, and its Inivata relationship is a clear example of promotion through collaboration. These alliances help put NeoGenomics in front of more pharma and clinical customers, especially in liquid biopsy and biomarker testing. Inivata’s precision oncology focus supports NeoGenomics’ effort to build trust through external validation.
- Inivata expands pharma-facing awareness
- Joint reach supports clinical customer growth
- Partnerships strengthen brand credibility
NeoGenomics Builds Trust with Specialist Growth
NeoGenomics promotes through direct sales, medical evidence, and pharma partnerships, not mass advertising. Its CLIA- and CAP-accredited labs support trust with hospitals, oncologists, and biopharma teams, while alliance-led visibility expands reach in liquid biopsy and biomarker testing. In 2025, annual revenue stayed above $600 million, backing its specialist brand.
| Promotion signal | Data point |
|---|---|
| Annual revenue | Over $600 million |
| Lab quality | CLIA and CAP accredited |
| Market focus | Hospitals, oncologists, pharma |
Price
Reimbursement-driven clinical pricing
NeoGenomics, Inc. uses reimbursement-driven clinical pricing, so most tests are billed as laboratory services and paid through payer contracts, not fixed sticker prices. The final price depends on the assay, medical-necessity coverage, and each payer’s rate; this is standard in diagnostics for hospitals and physicians. In 2024, U.S. Medicare Part B covered 67 million people, showing how payer rules can strongly shape lab revenue.
Contract pricing for Pharma Services
NeoGenomics, Inc. prices Pharma Services through negotiated contracts, not fixed list rates, so each drug-development client gets terms matched to project scope and testing volume. This model fits work that can range from small biomarker studies to larger development programs with added support needs. Custom pricing also helps align fees with changing assay demand and service complexity.
Test-specific pricing by complexity
NeoGenomics, Inc. prices tests by complexity: routine pathology costs less, while high-complexity oncology assays such as NGS, FISH, and MRD tests command higher prices because they need more technology, interpretation, and faster turnaround. The model fits its 2024 net revenue of $580.8 million, with advanced molecular work carrying the most value. In practice, price rises with assay depth, clinical urgency, and specialized lab inputs.
Third-party payer mix
NeoGenomics, Inc.’s clinical revenue depends on third-party payer mix, so realized price shifts with private insurers, Medicare, and other payers. Because each payer sets different contracted rates and reimbursement rules, the same test can collect different amounts. That makes cash inflow less predictable and ties pricing power to payer negotiations and claim approval rates.
- Private payers often pay higher rates.
- Medicare sets tighter fee schedules.
- Mix changes swing realized pricing.
Value-based specialist pricing
NeoGenomics, Inc. prices on clinical utility, not commodity volume, so its oncology tests can carry a premium over basic lab work. That fits a specialist model: customers pay for deeper diagnostic insight, broader test menus, and expert interpretation. The price strategy is built around expertise, breadth, and diagnostic depth.
- Premium tied to clinical utility
- Oncology focus supports higher pricing
- Depth and expertise drive value
NeoGenomics Pricing Is Driven by Payer Contracts and Test Mix
NeoGenomics, Inc. uses reimbursement-based pricing, so realized price depends on payer contracts, assay type, and medical-necessity approval rather than a fixed list rate. High-complexity oncology tests like NGS, FISH, and MRD usually carry higher rates because they need more technology and interpretation. In 2024, NeoGenomics, Inc. reported net revenue of $580.8 million, showing that price is tied to advanced test mix and payer economics.
| Metric | Value |
|---|---|
| Net revenue | $580.8 million |
| Pricing basis | Payer contract |
| Higher-price tests | NGS, FISH, MRD |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.